China Approves Blackstone & TPG’s $18.3 Bn Acquisition of Hologic

The approval marks a key regulatory milestone for the $18.3 billion transaction, including debt, which was announced in October.

China’s State Administration for Market Regulation (SAMR) has approved private equity firms Blackstone and TPG’s proposed acquisition of medical diagnostics company Hologic, according to a list of deal clearances released Tuesday.

The approval marks a key regulatory milestone for the $18.3 billion transaction, including debt, which was announced in October. The deal is considered the largest medical devices acquisition in nearly two decades.

Hologic develops and distributes medical imaging and diagnostic products primarily focused on women’s healthcare. The company maintains manufacturing operations and a partnership presence in China, bringing the transaction under the jurisdiction of Chinese antitrust authorities due to its business activities in the country.

SAMR did not specify whether the approval pertained to the acquisition of Hologic’s China-based units specifically or the broader global transaction. The regulator oversees mergers and acquisitions involving foreign companies that generate significant revenue or maintain substantial operations in China.

The acquisition will result in Hologic being taken private by Blackstone and TPG. The firms announced the agreement in October, outlining plans to acquire the company in a deal valued at $18.3 billion, including debt obligations.

The regulatory clearance from China follows similar approvals required across multiple jurisdictions for cross-border transactions of this scale. The companies have not publicly disclosed additional conditions tied to the Chinese approval.

Completion of the transaction remains subject to customary closing conditions and other regulatory approvals.

Stay tuned for more such updates on Digital Health News